Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1200351 | 0.85 | HPGD (0.49) | MAPTGAASMN1; SMN2HPGDNPSR1 | |
| SCHEMBL1200428 | 0.85 | ALDH1A1 (0.40) | MAPTGAASMN1; SMN2TSHRKDM4E | |
| SCHEMBL1200661 | 0.81 | HPGD (0.43) | MAPTGAASMN1; SMN2HPGDNPSR1 | |
| SCHEMBL29278476 | 0.77 | MAPT (0.50) | MAPTGAASMN1; SMN2HPGDNPSR1 | |
| SCHEMBL3548981 | 0.75 | MAPT (0.62) | MAPTGAASMN1; SMN2KDM4ETHRB | |
| SCHEMBL23536336 | 0.75 | MAPT (0.46) | MAPTGAASMN1; SMN2KDM4ETHRB | |
| SCHEMBL29932002 | 0.75 | MAPT (0.46) | MAPTGAASMN1; SMN2KDM4ETHRB | |
| SCHEMBL23555248 | 0.75 | CRHR1 (0.44) | MAPTGAASMN1; SMN2HPGDNPSR1 | |
| SCHEMBL2436520 | 0.72 | KDM4E (0.55) | MAPTGAASMN1; SMN2HPGDNPSR1 | |
| SCHEMBL24269710 | 0.72 | KMT2A (0.45) | MAPTGAASMN1; SMN2KDM4EGPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028469-A1 | Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor | ANDERSON ERIC C | 2011-02-03 | — | — | US | disclosed |
| US-20110028469-A1 | Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor | ANDERSON ERIC C | 2011-02-03 | — | — | US | disclosed |
| US-20110028469-A1 | Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor | ANDERSON ERIC C | 2011-02-03 | — | — | US | disclosed |
| EP-2207772-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS MODULATORS OF CCR9 RECEPTOR | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009044311-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS MODULATORS OF CCR9 RECEPTOR | ENCYSIVE PHARMACEUTICALS INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009044311-A1 | THIOPHENE-2-CARBOXAMIDE DERIVATIVES AS MODULATORS OF CCR9 RECEPTOR | ENCYSIVE PHARMACEUTICALS INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028469-A1 | Thiphene-2-Carboxamide Derivatives As Modulators of CCR9 Receptor | CCR9, CCR1, CCR10 | MAPT 3701/4885GAA 2884/4885SMN1; SMN2 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.